Mixed methods comparison of functional decline during chemotherapy, immunotherapy (IO), and/or targeted therapy in older adults with non-small cell lung cancer (NSCLC).

Melisa L. Wong,Alexander K. Smith,Christine Miaskowski,Vivek Musinipally,Harvey J. Cohen,Vivian Lam,Melissa Mazor,Carling Ursem,Kah Poh Loh,Jamie Alexis Cohen,Dianne M. Shumay,Anna Ordin Levin,Niharika Dixit,Janice Grandi,Louise C. Walter

Mixed methods comparison of functional decline during chemotherapy, immunotherapy (IO), and/or targeted therapy in older adults with non-small cell lung cancer (NSCLC).

2019

Melisa L. Wong
Alexander K. Smith
Christine Miaskowski
Vivek Musinipally
Harvey J. Cohen
Vivian Lam
Melissa Mazor
Carling Ursem
Kah Poh Loh
Jamie Alexis Cohen
Dianne M. Shumay
Anna Ordin Levin
Niharika Dixit
Janice Grandi
Louise C. Walter

92Background: Functional decline during NSCLC treatment is critically important to older adults. Yet, data on functional decline—particularly during chemoIO, IO, and targeted therapy—remain limited...

Keywords:

Immunotherapy
Oncology
Pathology
Internal medicine
non-small cell lung cancer (NSCLC)
Chemotherapy
Targeted therapy
Medicine
method comparison
functional decline

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations